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Abstract: 
Antiphospholipid syndrome (APS) is characterized by multiple arterial 
and/or venous thrombotic events, recurrent fetal losses in the presence of 
antiphospholipid antibodies. Catastrophic antiphospholipid syndrome 
(CAPS) is a life-threatening, rare subset of APS when the thrombotic 
events affect at least 3 organs, and clinical manifestations develop 
simultaneously or within a week. Diagnostically, small vessel occlusions 
can be detected by histopathology in the presence of antiphospholipid 
antibodies. Our case report describes a 18 years old man who has been 
treated with secondary APS (the underlying disease was Systemic Lupus 
Erythematosus) since 2011. The clinical findings were dominated by 




nephritis, accompanied by mild serological and laboratory findings. The 
patient was hospitalized in March 2014 because of severe 
thrombocytopenia and infective diarrhea. At this time the renal functions 
rapidly deteriorated. Simultaneously left upper extremity paresis was 
observed; CT showed ischemic lesions in the territory of the middle 
cerebral artery. Abdominal discomfort and pain occurred. On CT scan 
ischemic lesions could be seen in the spleen, in the right kidney and in the 
celiac trunk. Laboratory and serological findings verified the presence of 
antiphospholipid antibodies and anti-DNA antibodies, anemia and 
thrombocytopenia. Based on the above mentioned clinical and laboratory 
findings, the diagnosis of CAPS was established. Anticoagulation, 
corticosteroid, and plasmapheresis treatment, as well as hemodiafiltration 
were initiated. Although the thrombotic cascade decelerated following 
these interventions, we could not see improvement in the renal function. 
Rituximab treatment was started, leading to significant improvement in the 
renal function. After 5 weeks of treatment the patient was discharged from 
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Antiphospholipid syndrome (APS) is characterized by multiple arterial and/or venous 
thrombotic events, recurrent fetal losses in the presence of antiphospholipid antibodies. 
Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening, rare subset of APS 
when the thrombotic events affect at least 3 organs, and clinical manifestations develop 
simultaneously or within a week. Diagnostically, small vessel occlusions can be detected by 
histopathology in the presence of antiphospholipid antibodies. Our case report describes a 18 
years old man who has been treated with secondary APS (the underlying disease was 
Systemic Lupus Erythematosus) since 2011. The clinical findings were dominated by 
recurrent deep vein thrombosis, and severe proteinuria caused by lupus nephritis, 
accompanied by mild serological and laboratory findings. The patient was hospitalized in 
March 2014 because of severe thrombocytopenia and infective diarrhea. At this time the renal 
functions rapidly deteriorated. Simultaneously left upper extremity paresis was observed; CT 
showed ischemic lesions in the territory of the middle cerebral artery. Abdominal discomfort 
and pain occurred. On CT scan ischemic lesions could be seen in the spleen, in the right 
kidney and in the celiac trunk. Laboratory and serological findings verified the presence of 
antiphospholipid antibodies and anti-DNA antibodies, anemia and thrombocytopenia. Based 
on the above mentioned clinical and laboratory findings, the diagnosis of CAPS was 
established. Anticoagulation, corticosteroid, and plasmapheresis treatment, as well as 
hemodiafiltration were initiated. Although the thrombotic cascade decelerated following these 
interventions, we could not see improvement in the renal function. Rituximab treatment was 
started, leading to significant improvement in the renal function. After 5 weeks of treatment 
the patient was discharged from the hospital.  
Key words: SLE, thromboses, catastrophic antiphospholipid syndrome, rituximab 
Introduction 
Antiphospholipid syndrome (APS) is characterized by multiple arterial and/or venous 
thrombotic events, recurrent fetal losses in the presence of antiphospholipid antibodies.  The 
group of antiphospholipid antibodies consists of various members, such as lupus 
anticoagulant (LA), anti-cardiolipin antibodies (aCL) and anti-ß2-glycoprotein-I (aß2GPI) 
antibodies (1,2).  
Catastrophic antiphospholipid syndrome (CAPS) is a rare, severe, life-threatening subset of 
APS, which makes up less than 1% of all APS cases (3). According to the CAPS Registry, 

































































59% of the patients with CAPS had APS, while 26.9% suffered from SLE. In most of the 
cases, various pathogenic factors were verified, mainly infections. Most common infective 
agents are Salmonella, Escheria coli, Streptococcus, Staphylococcus (4). According to 
Asherson’s study the most frequent infections are respiratory, cutaneous, urinary tract, 
gastrointestinal infections and sepsis (5). 
Others triggering factors can be the discontinuation of anticoagulation therapy, oral 
contraceptives, or neoplasmas.  Recently it was published that besides infection 
thrombocytopenic state, low level of vitamin D and high level of ferritin also can induce 
CAPS (4). The pathomechanism of CAPS in not fully understood, while a series of 
pathogenic effects has been implicated.  Anti-phospholipid antibodies trigger a prothrombotic 
state, while inflammation ultimately leads to clot formation. Uncontrolled activation of the 
complement system also can initiate and amplify of pathological features of CAPS. Another 
mechanism is denoted as ‘cytokine storm’ which is caused by the release of proinflammatoric 
cytokines (IL-1, IL-5, IL-6, IFN-α, TNF-α) from affected tissues during thrombotic events 
mainly affecting the microvessels (4). The cytokines activate the innate immune system via 
TLR-4 production which can be induced by lipopolysacharides derived from bacteria (6). 
On the other hand, fibrinolysis is decreased, because of the high levels of plasminogen 
activator inhibitor-1 (PAI-1).   Asherson published the first diagnostic criteria for CAPS (7), 
later which was revised and is in use since then (8). According to the CAPS Registry the most 
frequently affected organs are the kidneys, lungs, brain, heart and the skin, while less 
frequently affected organs are the peripheral vessels, intestine, spleen, pancreas, retina and the 
bone marrow.  CAPS has a high mortality; before 2000 the mortality rate was 50% despite 
treatment (9). The therapy has three main aims. If there is an identifiable triggering factor, the 
treatment of that condition improves CAPS symptoms. In case of infection, antibiotics or 
antiviral therapy should be initiated. The other crucial point is to decelerate the thrombotic 
cascade and to suppress the cytokine storm, which leads to Systemic Inflammatory Response 
Syndrome (SIRS). The first line therapy consists of anticoagulation and corticosteroid 
treatment. Plasma exchange and/or intravenous immunoglobulin can have favorable effects on 
the disease course. If CAPS is associated with autoimmune disease, mainly SLE 
immunesupression could be considered. Cyclophosphamid is most frequently used in these 
cases. In therapy refractory or relapsing cases new therapeutic options need to be considered.  
Rituximab is a monoclonal antibody against CD20, which is expressed on B cells. Rituximab 
downregulates B-cell receptors and induce B-cell apoptosis. B-cell depletion may also reduce 

































































the production of proinflammatory cytokines which leads to the modulation of SIRS. 
Rituximab has been approved in non- Hodgkin lymphoma, rheumatoid arthritis, SLE.  There 
are ongoing clinical trials with rituximab in therapy resistant non-criteria manifestations, such 
as thrombocytopenia, ulcers, hemolytic anemia of APS.  According to the RITAPS trial 
rituximab was safe in APS patients, however rituximab has not induced changes in the 
antiphospholipid antibody profile, but it was effective in non-criteria manifestations of APS. 
(10) 
According to data from the CAPS registry, rituximab reduced mortality to 20%. Kidney 
involvement was the most frequent, followed by cardiac and cerebral involvement. Rituximab 
was second line therapy in 60% of the cases because of poor response to first line therapy, 
recurrent CAPS, therapy resistant thrombocytopenia or new thrombotic event (11,12).  
Over the last 15 years 4 patients have been treated with CAPS in our Department. The first 
cancer associated CAPS was published in 2000 (13).  The 45 years old woman was admitted 
to the ICU with neurological symptoms. The patient did not have APS or systemic 
autoimmune disease in her medical history.  The clinical situation was dominated by rapid 
onset of multiple thrombotic events which affected the brain, spleen, kidneys, lungs and the 
mitral valve with the presence of anti-cardiolipin and anti-beta2GPI antibodies, which 
fulfilled the diagnostic criteria for CAPS. The patient died in multi-organ failure after 2 weeks 
despite anticoagulation and corticosteroid treatment.  The predisposing factor was 
adenocarcinoma of the stomach, but it was revealed during autopsy. Our second case of 
CAPS was also associated with malignancy. The 62 years old woman was diagnosed with 
cytokeratin-7 positive endometrial cancer 1 year before CAPS was diagnosed. She was 
admitted to the hospital with pulmonary embolism. Anticoagulation therapy started. 
Pericardial and pleural effusion were revealed on echocardiography. Vascular ultrasound 
demonstrated the presence of thromboses in the internal jugular vein and inferior cava vein. 
Anticardiolipin IgG antibody positivity was tested. Her condition despite therapy deteriorated, 
the neurological status progressed to coma, intubation and mechanical ventilation was 
necessitated. 4 days after admission she died. Autopsy revealed multiple thromboses of the 
pelvic vein, portal and hepatic veins. Microtrombi was observed in the spleen. 
Immunehistochemical staining of the lungs showed cytokeratin-7 positivity, which indicated 
the metastasis of the previous endometrial cancer. The clinical picture supported the diagnose 
of CAPS which was verified by autopsy and histopathology (14). 

































































In our third case CAPS was associated with SLE.  SLE showed moderate and mild clinical 
and serological activity including antiphospholipid antibody positivity in low concentration 
(anti-β2-glycoprotein IgG and anti-prothrombin), but no thrombotic clinical symptoms have 
been observed. In December 2012 she was hospitalized due to pulmonary embolism preceded 
by a lower respiratory tract infection. Anticoagulation with therapeutic dose low molecular 
weight heparin (LMWH) have been started. Despite of anticoagulation, neurological 
symptoms appeared. Head CT showed cerebrovascular thromboses. Her condition rapidly 
deteriorated, multi-organ failure developed. Multiple infarctions in the spleen and kidneys 
could be detected in abdominal CT. Renal biopsy showed occlusive vasculopathy in the small 
vessels. Biopsy also proved chronic active mesangioproliferative glomerulonephritis with 
mesangial immune deposits. Lab tests indicated APA positivity in high titer. Overall, the 
clinical picture fulfilled the criteria of catasrophic antiphospholipid syndrome. In this case, 
CAPS was triggered by systemic autoimmune disease and infection. The anticoagulation and 
corticosteroid treatment was supplemented by high volume plasma exchange which was 
synchronized by intravenous immunoglobuline. Due to the immunmodulatory treatment the 
patient recovered. Since then no thrombotic events have been occurred, and clinically, the 
SLE symptoms are in remission.  
 
Methods 
The 19 years old, Caucasian, male patient was treated w th severe thrombocytopenia, indirect 
Coombs positivity and suffusions. Intravenous immunoglobulin was administered, 
thrombocyte level was normalized Immunological tests were performed which showed anti-
beta2GPI, anti-cardiolipin, and anti-phosphetidilserine antibody positivity, but there was no 
thrombotic event at that time.  In September 2010 he was diagnosed with deep vein 
thrombosis of the right femoral vein, as well as the communal and external iliacal vein. 
Thrombophilic tests (FII20210A, AT-III, PS and PC activity, FV Leiden, APS screening) 
were performed at the time; LA, aCL and aß2GPI antibodies were identified again. Oral 
anticoagulant therapy with vitamin K antagonist was started In 2011 he was diagnosed with 
SLE based on photosensitivity, lupus erythema and the presence of anti-nuclear, anti-SSA- 
anti-SSB antibody, anti-CL antibodies and hypocomplementaemia, as well as positive LA. 
The diagnosis of secondary APS was also established based on the clinical picture and 
laboratory findings.  The maintenance therapy was corticosteroid, hydroxycloroquine and 

































































anticoagulation. During the next 2 years he has been in remission. He had mild symptoms of 
arthralgia, skin involvrment and mild upper airway tract infections. 
During the autumn of 2013 he was hospitalized several times because of high sedimentation 
rate, massive proteinuria (10 g/day), massive edema on the legs, increasing levels of 
carbamide, creatinine, worsening anemia and thrombocytopenia. After pulse corticosteroid 
treatment (3x1000mg), the platelet counts increased. Due to deteriorating renal function and 
massive proteinuria, as the sign of the activation of lupus, mycophenolate mofetil treatment 
was initiated. In January 2013 he was hospitalized because of recurrent deep vein thrombosis 
in his right superficial femoral vein. Low molecular weight heparin therapy was administered. 
The therapy was modified due to recurrent thromboses and activation of SLE: 
Cyclophosphamid was initiated with good therapeutic response; the proteinuria diminished 
and the renal functions slightly improved.  
In March 2014 he was hospitalized for the next cycle of cyclophosphamide therapy. However, 
he could not get the next cycle of cyclosphamide because the platelet count was under 150 
G/L. In the physical status, swollen lilac lips, epigastric pain, edema of the lower right 
extremity and diarrhea could be outlined. The lab test showed high CRP levels (90.51 mg/mL; 
normal range: <4.6 mg/L) leukocytosis (12.72 G/L; normal range:4.5-10.8 G/L),  
thromobocytopenia (31 G/L; normal range: 150-400 G/L) and anemia (Hgb: 123 g/L; normal 
range:130-165 g/L),  increased carbamide  (23.3  mmol/L; normal range: 3.6-6 mmol/L) and 
creatinine (464  µmol/L; normal range: 44-97 µmol/L) levels, hypoproteinemia (52 g/L; 
normal range: >60 g/L) and high fibrinogen levels (9.29 g/L; normal range:1,5-4 g/L). The 
clinical picture and the lab tests confirmed the diagnosis of gastrointestinal infection.  
Metronidazole was initiated. In the next few days the gastrointestinal symptoms diminished, 
however the renal failure, anemia, thrombocytopenia progressed and in the quantitative blood 
smear fragmentocytes were detected. Subsequently paresis of the left upper extremity 
appeared. Skull CT showed ischemic lesion at the territory of the right medial cerebral artery 
(Figure 1A). Due to exceeding gastrointestinal pain, abdominal CT was performed, which 
detected thrombus in the lumen of the celiac trunk (Figure 1B), infarction in the spleen 
(Figure 1C) and in the right kidney (Figure 1D). Lab tests revealed anti-double stranded 
DNA, anti-beta-GPI positivity. As a differential diagnosis thrombotic trombocytopenic 
purpura/hemolytic uremic syndrome (TTP/HUS) was established, however it was ruled out by 
negative results on ADAMTS 13 and anti-Factor H antibody assessment. Renal biopsy was 
performed which revealed thrombotic nephropathy. Immunohistochemistry showed 

































































microthrombi which occluded the glomerular capillaries. The biopsy specimen revealed SLE-
associated chronic glomerular damage exhibiting scattered thrombotic occlusions of the 
capillary tufts reflecting CAPS (Figure 2.). Immunofluorescent staining for fibrin confirmed 
that the glomerular capillary tufts' occlusions (long arrows) and the interstitial vascular 
obstructions (thick arrows) correspond to fibrin-rich thrombi (green fluorescence), suggestive 
of renal manifestation of CAPS (original magnification: 40x; nuclear counterstain is with the 
blue fluorescent DAPI). Both confirm the multiple intraglomerular fibrin- thrombi (arrows) 
which in part are found along the intimal-subendothelial region of the capillary tuft (image C, 
arrows). Electron microscopy (EM) exhibited glomeruli with basement membrane (BM) 
thickening and endothelial-subendothelial damages associated with CAPS (Figure 3). 
Moreover, higher magnification (10000x) identifies splitting and dissection of the endothelial 
cells from the BM in association with electron-lucent subendothelial (SE) amorphous material 
deposition admixed with tissue debris. Finally, double immunofluorescent labeling of the 
biopsy specimens identified the presence of the membrane-attack complex of the complement 
cascade that showed unambiguous evidence of endothelial and subendothelial deposition and 
insudation of C9 that is predominantly manifested along the glomerular capillary tufts and in 
part within the vasculature of the interstitial spaces (Figure 4). Further stainings for T- and B-
cells showed the immune-inflammatory cellular composition of the SLE-associated CAPS in 
this case, demonstrating that both the T-cells and the B-lymphocytes could be considered to 
have roles in the pathomechanism of the vascular damage resulting in thrombotic occlusions 
(Figure 4).  
 
Results 
Based on the clinical features histology and laboratorial findings, the diagnosis of 
gastrointestinal infection induced CAPS on the grounds of SLE, perpetuated by the 
complement cascade and T-/B-lymphocytes was established.  
The primary goal of the therapeutic plan was to decelerate the thrombotic cascade and to 
suppress inflammatory cytokines. LMWH treatment was continued but in lower dosage 
(2x0.2 ml) in order to avoid bleeding in the ischemic lesion of the territory at the right medial 
cerebral artery. The dose of corticosteroid was increased to 80 mg per day. Plasmapheresis 
treatment (40 ml/ kg) was performed 6 times. Hemodiafiltration treatment was performed 3 
times because of the acute renal failure and increasing levels of carbamide and creatinine. 

































































After 6 plasmapheresis cycles, along with the corticosteroid and LMWH treatment, the 
paresis slightly resolved, and the hematological parameters began to normalize.  However, no 
significant improvement could be achieved in the renal function. The therapeutic regime was 
therefore supplemented with Rituximab. 1000 mg Rituximab was given two times and the 
treatment led to the significant improvement of the acute renal failure. Depicts the efficacy of 
therapy on renal failure. After 5 weeks the patient was discharged from the hospital with 
normal laboratory parameters and good general health condition.  After 1 year the patient had 
a grand mal seizure at home. He was admitted to the local hospital where skull CT was 
performed. The CT scan could not verify new ischemic lesion or bleeding. He was transferred 
to our intensive care unit. Upon arrival he was cardio-respiratory compensated. Lab tests 
revealed normal Hgb, platelet, leucocytes levels. The CRP, PCT was in normal range, which 
ruled out any underlying infective cause. Antiphospholipid antibodies were negative, as well. 
On the first day grand mal seizure appeared again, which was followed by Todd paresis. To 
ease the seizure 4mg midazolam and 10 mg diazepam was given intravenously. Possibly the 
seizures were caused by the central nervous system involvement of SLE. To rule out cerebral 
vasculitis skull MR was performed, which only showed the signs of previous ischemic 
lesions. Vasculitis, bleeding or new thrombotic event could not be detected on MR. EEG was 
also performed which detected epileptic activity. The therapy was supplemented by 
carbamazepine. During hospitalization epileptic seizures were not repeated. Neither 
thrombotic events, nor kidney failure appeared. The kidney function was compensated. The 
carbamide level was 10.4 mmol/l, while creatinine was 158 umol/l. During urine analysis 
proteinuria could not be detected. He was discharged from the hospital after 1 week in a good 
overall condition. Since then he is free of seizures, he takes 400 mg carbamazepine daily. SLE 
is in remission with the maintenance therapy of corticosteroid, hydroxycloroquine and 
anticoagulation.  
Discussion 
This complex case shows multi-organ thrombotic escalation. We believe that in this patient 
the concomitant infection initiated pathological processes, such as binding of 
antiphospholipid antibodies to the endothelium, followed by complement activation. The 
accelerated complement activation, therefore, as a second hit led to the development of 
catastrophic thrombotic manifestations. We also showed the intrarenal accumulation of 
lymphocytes, both T- and B-cells, assuming that these cells also play a role in the 

































































development of renal pathology. These findings may explain the favorable effect of 
Rituximab treatment on renal function, which is beneficial for decelerating lupus-associated 
humoral autoimmune processes, as well as the CAPS-associated pro-thrombotic 
antiphospholipid antibody production. In our case immunohistochemistry reinforced the 
double-hit theory in CAPS development, identifying the presence of complements, as well as 
B-cells intrarenally, giving rise to the beneficial effects of using plasmapheresis and 
Rituximab in the disease management. 
In the standard management of CAPS anticoagulation, corticosteroid, plasmapheresis and 
immunemodulatory treatment is utilized, as well as the targeted therapy of other etiological 
factors (e.g. infections) is pivotal. However, in certain cases, the modulation or depletion of B 
cells can be necessary, as the source of autoantibodies and pro-inflammatory cytokines (7). 
According to the CAPS Registry only 20 cases treated with Rituximab have been reported so 
far (8). In most cases it was a second line treatment, based on poor therapeutic response to 
first line therapy. In 4 cases Rituximab was the first line therapy because of associated 
lymphoma or very severe, other life-threatening medical conditions. Among patients treated 
with Rituximab, the mortality decreased to 20%; among the treated patients 4 out of 20 died 
(8). 
Conclusion 
 We believe that in our patient, the identification of intrarenal complement activation 
and T/B lymphocytic infiltration along with diffuse microthrombus formation aid in 
understanding the pathomechanism of lupus-associated CAPS triggered by infection. Based 
on histological evidence a combination therapy, including Rituximab treatment was used 
successfully, due to non-responding acute renal failure. After rituximab treatment the 
antiphospholipid antibody profile has been changed. According to data from the CAPS 
registry the effect of rituximab on antiphospholipid antibodies was controversial. In most 
cases the antibody profile did not change after rituximab treatment.  Overall we suggest that 
in these patients B-cell depletion or plasma cell modulation can be considered and can be 
beneficial.                                                                                                                                      
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Legend to figures 
Figure 1. CT image of ischaemic laesion (A), thrombus in the coliac trunk (B), spleen 
infarction (C) and kidney infarction (D) 
 
Figure 2.  
Hematoxylin-eosin (HE) stained glomerular biopsy specimen (A), Immunofluorescent 




Electron microscopy (EM) specimens of glomeruli. Screening magnification (3000x) (A), 
Higher magnification (10000x) (B) 
 
Figure 4. 
Double immunofluorescent labeling of the membrane-attack complex  (A) and the pan-T-cell 









































































Figure 1. CT image of ischaemic laesion (A), thrombus in the coliac trunk (B), spleen infarction (C) and 
kidney infarction (D)  
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Figure 2.  
Hematoxylin-eosin (HE) stained glomerular biopsy specimen (A), Immunofluorescent staining for fibrin (B), 
Trichrome special stainings  of multiple intraglomerular fibrin- thrombi (C-D)  
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Figure 3.  
Electron microscopy (EM) specimens of glomeruli. Screening magnification (3000x) (A), Higher 
magnification (10000x) (B)  
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Figure 4.  
Double immunofluorescent labeling of the membrane-attack complex  (A) and the pan-T-cell combined with 
the pan-B-cell marker to show the immune-inflammatory cellular composition (B)  
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